Shanghai, China - September 8, 2025. Shanghai Escugen Biotechnology Co., Ltd. ("Escugen") and Huahui Health (Beijing) Biotechnology Co., Ltd. ("Huahui Health") announced today that they have entered into an exclusive global cooperation and development agreement for a novel, undisclosed tumor target. The partnership aims to jointly develop a potential "First-in-Class" antibody-drug conjugate (ADC) candidate.
This cooperation will fully leverage the advantages of Escugen's independently developed EZWi-Fit® ADC platform technology, combined with Huahui Health's capability in developing highly tumor-specific fully human antibodies. It will achieve an organic integration of technology and innovation, enhancing the market competitiveness and therapeutic value of the resulting ADC drug. According to the plan, the two parties will work together to advance the candidate into clinical development, targeting multiple solid tumors with significant unmet medical needs.
Dr. Zhou Qing, founder and CEO of Escugen, stated that relying on Huahui Health's excellent antibody engineering technology, this target has shown significant potential. Combined with Escugen's EZWi-Fit® platform, which has been validated in multiple preclinical and clinical projects, we are expected to jointly push this candidate drug to new heights, expanding its therapeutic window and enhancing its resistance threshold.
Dr. Chen Bin, CEO of Huahui Health, expressed that Escugen's EZWi-Fit® technology platform has been clinically validated. By integrating it with Huahui Health's novel engineered antibodies, we anticipate that the co-developed First-in-Class ADC candidate will demonstrate clinical advantages over existing treatment options.
About Huahui Health
Founded in 2015, Huahui Health is committed to developing innovative therapies for liver diseases and oncology, with a focus on chronic hepatitis B and D (HBV and HDV), two of the world’s most prevalent and devastating infectious diseases. Leveraging deep expertise in disease biology and protein engineering, we have further expanded our pipeline to include multiple first- and best-in-class candidates in the area. Guided by our core values—Innovation, Truth-Seeking, and Collaboration—we strive to become a globally respected leader in biopharmaceuticals.
About Escugen
Escugen is a clinical-stage biotechnology company located in Shanghai, China, focusing on the development of innovative ADC drugs. Currently, Escugen's lead Trop-2 ADC pipeline, ESG401, has entered Phase III clinical trials. Escugen's next-generation linker-payload technology platform, EZWi-Fit®, offers significant competitive advantages in terms of safety, efficacy, anti-multiple drug resistance, and pharmacokinetic characteristics. Leveraging this platform technology, Escugen is rapidly expanding its ADC pipeline targeting new or validated target. The first ADC product baring the EZWi-Fit® technology has successfully launched its FIH clinical campaign. In addition, Escugen has licensed this platform technology to several domestic and international biotechnology companies to empower their innovative ADC projects.
